hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06310954 id: 2022-KY-012 briefTitle: Ketogenic Diet in Pediatric Intractable Epilepsy overallStatus: RECRUITING date: 2022-08-11 date: 2024-04-30 date: 2024-04-30 date: 2024-03-15 date: 2024-03-15 name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University class: OTHER briefSummary: This study aims to evaluate the efficacy of a ketogenic diet in treating pediatric intractable epilepsy and to explore its relationship with changes in inflammatory markers. The investigators plan to recruit 59 participants with intractable epilepsy, 39 of whom will receive a combination of ketogenic diet and conventional antiepileptic drugs, while 20 will receive only conventional drugs. The study will assess the impact of the ketogenic diet on epilepsy control and inflammatory markers, hoping to discover new treatment strategies. conditions: Epilepsy in Children conditions: Epilepsy Intractable studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 59 type: ESTIMATED name: Early ketogenic diet combined with conventional pharmacotherapy. name: Common diet combined with conventional pharmacotherapy measure: Epilepsy Control Response Rate measure: Inflammatory Marker Levels sex: ALL minimumAge: 6 Months maximumAge: 12 Years stdAges: CHILD facility: Sun Yat Sen Memorial Hospital， Sun Yat Sen University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: Dongfang Li role: CONTACT phone: +8615521284993 email: ldf201310@163.com name: Dongfang Li role: PRINCIPAL_INVESTIGATOR lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06310941 id: ABSENTA id: Pending type: OTHER domain: Ceim HCSC (ERB of Hospital Clinico San Carlos)) briefTitle: Mechanical Insufflation-exsufflation and Hypertonic Saline in Nosocomial Bacterial Respiratory Tract Infection acronym: ABSENTA overallStatus: NOT_YET_RECRUITING date: 2024-12-01 date: 2026-10-30 date: 2026-12-30 date: 2024-03-15 date: 2024-03-15 name: Hospital San Carlos, Madrid class: OTHER briefSummary: Randomized open label clinical trial to evaluate IEM and HS as concomitant therapy for respiratory tract infection in patients under artificial ventilation in the ICU.
Current specific treatment consists of intravenous antibiotics. The current study evaluated whether aspiration and drainage of infected sputum helps curing this severe complication and whether nebulized HS has additional benefits, like eradicating bacteria or reducing inflammation. conditions: Nosocomial Infection conditions: Nosocomial Pneumonia conditions: Tracheobronchitis conditions: Mechanical Ventilation Complication conditions: Endotracheal Intubation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: randomized, open label primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Mechanical insufflation-exsufflation name: Standard of Care name: Hypertonic saline with hyaluronic acid measure: Median SOFA score increase >2 points on day 4 measure: Median respiratory support-free days increase at day 28 measure: Percentage of subjects surviving/dying day 28 measure: Subjects with bacterial eradication in respiratory samples at day 4 after randomization measure: Subjects with bacterial eradication in respiratory samples at end of systemic antibiotic therapy measure: Median Length of ICU stay measure: Median antibiotic-free days at 28 days sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310928 id: SBU-201001077-2022 briefTitle: The Effect of Thermal Blanket After Peripheral Artery Surgery overallStatus: RECRUITING date: 2022-05-20 date: 2024-03 date: 2024-03 date: 2024-03-15 date: 2024-03-15 name: Saglik Bilimleri Universitesi class: OTHER briefSummary: Peripheral arterial disease is one of the most common clinical conditions associated with cardiovascular morbidity and increased mortality, requiring exercise, antiaggregant and surgical revascularization therapy. As in peripheral arterial surgery, postoperative hypothermia is common in patients who have undergone surgical intervention and the duration of surgery is longer than 30 minutes due to the low temperature of the surgical environment or the suppression of the thermoregulation center by anesthetics and sedatives. With hypothermia, heat loss increases,peripheral vasoconstriction with activation of the sympathetic system, impaired perfusion at the surgical wound site, hypoxemia, coagulopathy, bleeding, postoperative pain, deterioration of thermal comfort, deterioration of patient comfort and prolonged hospital stay are reported. Many heating methods are used to achieve and maintain normal body temperature in the postoperative period, to prevent complications caused by hypothermia.Aluminum-coated thermal blankets are especially preferred. In this way, heat preservation, peripheral vasodilation and perfusion with the effect of temperature, reduction of muscle spasm with increased endorphin release, less pain, and increased comfort of the patient are provided. The thermal blanket is an easy-to-apply material that does not require any tools or electricity for its effectiveness and can come into direct contact with the patient's skin. It provides thermal insulation with its ability to reflect thermal radiation. Peripheral vasodilation and decreased peripheral vascular resistance have been observed with thermal therapy provided by thermal blankets. It is known that thermal blanket methods are used to warm patients in practice. However, the lack of a literature study on the regional effect of these applications on the patient has been noticed. For this purpose, in this study, the regional efficacy of thermal blankets on the patient was evaluated in order to reduce the narrowed arterial lumen and increased peripheral vascular resistance in peripheral arterial diseases and to prevent the vasoconstrictive effect of hypothermia on peripheral vessels. It was predicted that these blankets would maintain heat, increase tissue perfusion with peripheral vasodilation effect, facilitate circulation, reduce pain and facilitate mobilization.In line with this aim, the objectives are;
Research Design This study is a randomized controlled trial to determine the effect of a thermal blanket applied to the area after peripheral arterial surgery on the patient's circulation, pain and mobilization. conditions: Peripheral Arterial Disease studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is a single center randomized controlled clinical trial.The sample consisted of a total of 60 patients who would undergo interventional peripheral arterial surgery, met the study criteria and agreed to participate in this study. They will be divided into two groups as 30 experimental group and 30 control group by randomization method. primaryPurpose: OTHER masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Thermal Blanket measure: The Effect of Thermal Blanket Applied to the Area After Peripheral Artery Surgery on Circulation measure: The Effect of Thermal Blanket Applied to the Area After Peripheral Artery Surgery on Pain measure: The Effect of Thermal Blanket Applied to the Area After Peripheral Artery Surgery on Mobilization sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sağlık Bilimleri University status: RECRUITING city: Istanbul state: Uskudar zip: 34674 country: Turkey name: BIRGUL AYDOGAN, RN role: CONTACT phone: +905336337651 email: 201001077@ogrenci.sbu.edu.tr name: SONAY GÖKTAŞ, PROF.DR. role: CONTACT phone: +905324567776 email: sonay.goktas@sbu.edu.tr lat: 41.01384 lon: 28.94966 hasResults: False
nctId: NCT06310915 id: CROC202310 briefTitle: Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor overallStatus: RECRUITING date: 2023-03-17 date: 2025-03 date: 2025-05 date: 2024-03-15 date: 2024-03-15 name: Guangzhou Institute of Respiratory Disease class: OTHER briefSummary: Oral chemotherapeutic drugs were analyzed in patients with driver gene negative locally advanced/advanced non-small cell lung cancer with PS score 2 A prospective, single-arm, multicenter, observational study on the efficacy and safety of radiochemotherapy combined with PD-1 inhibitor. conditions: Non-small Cell Lung Cancer Stage IIIB/IV studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 30 type: ESTIMATED name: Navelbine oral,Pembrolizumab measure: Progression-free survival time sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Guangzhou Medical University status: RECRUITING city: Guangdong state: Guangzhou zip: 510000 country: China name: zhou chegnzhi, doctor role: CONTACT phone: 13560351186 email: doctorzcz@163.com hasResults: False
nctId: NCT06310902 id: 2024KY022 briefTitle: Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients overallStatus: RECRUITING date: 2024-03-01 date: 2026-03-01 date: 2026-09-01 date: 2024-03-15 date: 2024-03-15 name: Fujian Medical University Union Hospital class: OTHER briefSummary: Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group. conditions: Pancreatic Neoplasms studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Single-cell Sequencing Analysis measure: Bioinformatics analysis of single-cell sequencing results sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fujian Medical University Union Hospital status: RECRUITING city: Fuzhou state: Fujian zip: 350001 country: China name: Yu Pan, M.D role: CONTACT phone: +86 18900316399 email: yupan199002@163.com lat: 26.06139 lon: 119.30611 hasResults: False
nctId: NCT06310889 id: EPIC-Baseline-Survey briefTitle: Evaluation of Palliative Care Co-treatment by Attending Physicians and Nurses: an Online Survey as Part of the Project acronym: EPIC-BS overallStatus: WITHDRAWN date: 2024-04-01 date: 2024-06-30 date: 2024-06-30 date: 2024-03-15 date: 2024-03-18 name: Charite University, Berlin, Germany class: OTHER name: European Commission name: National and Kapodistrian University of Athens name: King's College Hospital NHS Trust briefSummary: The subject of the study is an online survey of doctors and nurses who provide (intensive) medical care to patients. conditions: Palliative Medicine studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 0 type: ACTUAL measure: Barriers 1 measure: Barriers 2 measure: Measures 1 measure: Measures 2 measure: Resources 1 measure: Resources 2 sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06310876 id: M24-852 briefTitle: A Thorough QT Study of ABBV-CLS-7262 in Healthy Subjects overallStatus: RECRUITING date: 2024-03-14 date: 2024-06 date: 2024-07 date: 2024-03-15 date: 2024-03-29 name: Calico Life Sciences LLC class: INDUSTRY name: AbbVie briefSummary: This is a randomized, blinded, placebo and active-controlled, 4-period, crossover design thorough QT/QTc (TQT) study to evaluate the effect of ABBV-CLS-7262 on cardiac repolarization in healthy adult subjects. conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 72 type: ESTIMATED name: ABBV-CLS-7262 name: ABBV-CLS-7262 name: Placebo name: Moxifloxacin 400mg measure: To evaluate the effect of ABBV-CLS-7262 on the QTc interval in healthy adult subjects measure: To evaluate the effects of ABBV-CLS-7262 on change in electrocardiogram (ECG) parameters measure: To evaluate the sensitivity of QTc measurement using moxifloxacin measure: To evaluate the effect of ABBV-CLS-7262 on T-wave morphology sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: AbbVie Clinical Pharmacology Research Unit (ACPRU) status: RECRUITING city: Grayslake state: Illinois zip: 60030 country: United States lat: 42.34447 lon: -88.04175 hasResults: False
nctId: NCT06310863 id: EXOCOBIO-NASAL-01 briefTitle: Pivotal Study to Evaluate the Efficacy and Safety of Injection With LASBEAU Strong in Correction of Nasolabial Folds overallStatus: COMPLETED date: 2019-10-07 date: 2020-11-24 date: 2020-11-24 date: 2024-03-15 date: 2024-03-15 name: Asan Medical Center class: OTHER briefSummary: Background: Nonsurgical injectable treatments have become popular for aesthetic purposes. In recent years, cross-linked hyaluronic acid (HA) fillers containing lidocaine have been used to correct the nasolabial folds.
Patients/methods: A total of 72 subjects were enrolled and randomized to receive injections of the new HA filler (test group) or the conventional HA filler (control group) on the left or right side of the face. The mean value difference in the Wrinkle Severity Rating Scale (WSRS) scores at week 24 evaluated primary efficacy. The WSRS and the Global Aesthetic Improvement Scale (GAIS) at weeks 8, 16, 24, and 48 evaluated secondary efficacy. Adverse events, laboratory tests, and a check of vital signs at every visit assessed safety. conditions: Dermal Fillers studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, Matched pairs, Active controlled primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 72 type: ACTUAL name: LASBEAU Strong or Restylane Lyft injection as hyaluronic acid fillers measure: Differences in the mean value of the Wrinkle Severity Rating Scale (WSRS) between the test group and the control group measure: The mean value differences in the WSRS scores between the test group and the control group measure: Differences in GAIS mean values between test and control groups measure: Percentage of subjects with WSRS score improvement of at least 1 point sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Asan mediccal center city: Seoul state: Songpa-gu zip: 05505 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06310850 id: KEAH-238 briefTitle: The Effect of Preprocedural Subanesthetic Ketamine on Pain and Anxiety overallStatus: COMPLETED date: 2013-06-01 date: 2023-01-01 date: 2023-06-01 date: 2024-03-15 date: 2024-03-15 name: Ankara Ataturk Sanatorium Training and Research Hospital class: OTHER_GOV briefSummary: The thoracic epidural catheterization (TEC) can be both uncomfortable and fearful for patients when done awake with the thought that the procedure may be painful. The aim of this study was to assess the effect of subanesthetic intravenous ketamine administration on pain and anxiety during the TEC procedure. conditions: Epidural Catheterization conditions: Thoracic conditions: Procedural Pain studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study was designed as a randomized, prospective study primaryPurpose: PREVENTION masking: SINGLE whoMasked: PARTICIPANT count: 60 type: ACTUAL name: Ketamine name: Placebo measure: Visual analog scale (VAS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ankara Atatürk Sanatorium Training and Research Hospital city: Ankara state: Keçiören zip: 06290 country: Turkey lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06310837 id: 2023KYPJ300 briefTitle: Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis overallStatus: NOT_YET_RECRUITING date: 2024-03-27 date: 2024-08-27 date: 2025-06-30 date: 2024-03-15 date: 2024-03-15 name: Zhongshan Ophthalmic Center, Sun Yat-sen University class: OTHER name: The Eye Hospital of Wenzhou Medical University name: The First Affiliated Hospital of Soochow University name: Shandong Eye Hospital briefSummary: This is a multi-center, prospective, randomized controlled non-inferior clinical study. A total of 120 subjects with non-infectious intermediate, posterior, or panuveitis were enrolled in Zhongshan Ophthalmic Center and three other centers. They were randomly assigned to the experimental group and the control group according to ( 1 : 1 ). We hypothesized that adalimumab biosimilars combined with immunosuppressive agents in the treatment of non-infectious uveitis is not inferior to glucocorticoids combined with immunosuppressive agents, and there are no additional adverse events and safety issues. conditions: Uveitis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 120 type: ESTIMATED name: Adalimumab Biosimilars Injection name: Corticosteroid name: Immunosuppressive Agents measure: Change of ETDRS letter count for BCVA at week 24 from baseline measure: Proportion of patients with weight gain at week 24 from baseline measure: Time of treatment failures measure: Number of treatment failures measure: Change of Visual Functioning Questionnaire- 25 (VFQ-25) composite score from baseline measure: Change of anterior chamber inflammation at week 24 from baseline measure: Change of vitreous opacity at week 24 from baseline measure: Change of the retinal and choroidal inflammation at week 24 from baseline measure: Change of the thickness of retina and choroid in macular area at week 24 from baseline measure: Occurrence of skin abnormalities at the end of study measure: Occurrence of hypertension at the end of study measure: Occurrence of hyperglycemia at the end of study measure: Occurrence of active tuberculosis infection at the end of study sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhongshan Ophthalmic Center city: Guangzhou state: Guangdong zip: 510060 country: China name: Wei Chi role: CONTACT phone: 13710616456 email: chiwei@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06310824 id: MAB-22-101 briefTitle: Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-07 date: 2025-07 date: 2024-03-15 date: 2024-03-18 name: Xentria, Inc. class: INDUSTRY briefSummary: A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three-arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® conditions: Healthy Participants studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 225 type: ESTIMATED name: MAB-22 name: EU-Prolia® name: US-Prolia® measure: Area under the concentration-time curve from time 0 extrapolated to infinity (AUC0-∞) measure: Maximum observed serum concentration (Cmax) measure: Area under the concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last) measure: Area under the concentration-time curve measure: Area under the concentration-time curve sex: MALE minimumAge: 25 Years maximumAge: 55 Years stdAges: ADULT hasResults: False
nctId: NCT06310811 id: BHCT-RD06-04-01 briefTitle: Anti-CD19 CAR-T Cell Therapy in Participants With Moderate to Severe Active Systemic Lupus Erythematosus overallStatus: RECRUITING date: 2024-03-07 date: 2025-03-01 date: 2027-03-01 date: 2024-03-15 date: 2024-03-15 name: Wuhan Union Hospital, China class: OTHER briefSummary: This is an open, Phase I, investigator-initiated study (IIT) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-04 in patients with moderate or severe active SLE.
2. If 1 case of DLT occurs in each dose group, the dose level will be extended to 6 subjects. If 6 subjects at this dose level ≥2 subjects develop DLT, the dose level exceeds the MTD. The previous lower dose level will be extended to 6 subjects, and if 6 subjects have already been enrolled in the previous lower dose level, and only ≤1 of these 6 subjects develop DLT, this lower dose level will be considered MTD.
After the completion of DLT evaluation in all dose groups, the investigators could select the corresponding dose group of extended cases according to the treatment response, but the total number of cases should not exceed 12 (extended cases were not evaluated by DLT). conditions: Safety conditions: Effective studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: All patients will be treated with RD06-04 cell injections in a single group primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: RD06-04 Cells injection measure: Incidence of dose-limiting toxicity (DLT) measure: The incidence of treatment-based adverse events (TEAEs) and the incidence of serious adverse events (SAEs). sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Wuhan Union status: RECRUITING city: Wuhan state: Hubei zip: 430000 country: China name: Heng Mei, Chief physician role: CONTACT phone: 13886160811 email: hmei@hust.edu.cn lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06310798 id: Dnr. 2020-04603 briefTitle: Inter-organizational Health Planning for Older Adults: Public Dental Care and Municipal Care acronym: GAPA overallStatus: NOT_YET_RECRUITING date: 2025-03-01 date: 2025-05-15 date: 2026-03-01 date: 2024-03-15 date: 2024-03-15 name: Vastra Gotaland Region class: OTHER_GOV name: Göteborg University name: Gothia Forum - Center for Clinical Trial name: Chalmers University of Technology briefSummary: Patient participation is key for healthy ageing and essential in health planning and decision-making. Oral health is an important but sometimes neglected part of general health and there is little research on health planning in ordinary home settings where older adults, dental and nursing staff participate. It has been concluded that shared tools, such as common documentation, and working in teams enables person-centered care in ordinary home settings. Therefore, this protocol outlines the design of a randomized controlled trial (RCT) measuring and comparing effect of two models of team based oral health planning with a common tool (digital platform) in ordinary home care settings in Sweden. The overall aim of this project is to evaluate a person-centered inter-professional and inter-organizational model for oral health planning supported by a digital platform to enable healthy ageing.